Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib, SC Trastuzumab, and Capecitabine Neoadjuvant Therapy for HER2+ Breast Cancer
NCT06483386Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06483386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483386.